430 related articles for article (PubMed ID: 28123146)
1. Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.
Guolo F; Minetto P; Clavio M; Miglino M; Lemoli RM; Gobbi M
Biosci Trends; 2017 Mar; 11(1):110-114. PubMed ID: 28123146
[TBL] [Abstract][Full Text] [Related]
2. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients.
Guolo F; Minetto P; Clavio M; Miglino M; Di Grazia C; Ballerini F; Pastori G; Guardo D; Colombo N; Kunkl A; Fugazza G; Rebesco B; Sessarego M; Lemoli RM; Bacigalupo A; Gobbi M
Am J Hematol; 2016 Aug; 91(8):755-62. PubMed ID: 27084986
[TBL] [Abstract][Full Text] [Related]
3. Fludarabine, cytarabine, granulocyte colony-stimulating factor and idarubicin for relapsed childhood acute myeloid leukemia.
Nakayama H; Tomizawa D; Tanaka S; Iwamoto S; Shimada A; Saito AM; Yamashita Y; Moritake H; Terui K; Taga T; Matsuo H; Kosaka Y; Koh K; Hosoi H; Kurosawa H; Isoyama K; Horibe K; Mizutani S; Adachi S
Pediatr Int; 2017 Oct; 59(10):1046-1052. PubMed ID: 28771903
[TBL] [Abstract][Full Text] [Related]
4. Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.
Burnett AK; Russell NH; Hills RK; Hunter AE; Kjeldsen L; Yin J; Gibson BE; Wheatley K; Milligan D
J Clin Oncol; 2013 Sep; 31(27):3360-8. PubMed ID: 23940227
[TBL] [Abstract][Full Text] [Related]
5. Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years.
Candoni A; Martinelli G; Toffoletti E; Chiarvesio A; Tiribelli M; Malagola M; Piccaluga PP; Michelutti A; Simeone E; Damiani D; Russo D; Fanin R
Leuk Res; 2008 Dec; 32(12):1800-8. PubMed ID: 18621416
[TBL] [Abstract][Full Text] [Related]
6. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
[TBL] [Abstract][Full Text] [Related]
7. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
[TBL] [Abstract][Full Text] [Related]
8. Flai (fludarabine, cytarabine, idarubicin) plus low-dose Gemtuzumab Ozogamicin as induction therapy in CD33-positive AML: Final results and long term outcome of a phase II multicenter clinical trial.
Candoni A; Papayannidis C; Martinelli G; Simeone E; Gottardi M; Iacobucci I; Gherlinzoni F; Visani G; Baccarani M; Fanin R
Am J Hematol; 2018 May; 93(5):655-663. PubMed ID: 29396857
[TBL] [Abstract][Full Text] [Related]
9. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Choi Y; Lee KH;
Eur J Haematol; 2016 Feb; 96(2):188-97. PubMed ID: 25891993
[TBL] [Abstract][Full Text] [Related]
10. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
[TBL] [Abstract][Full Text] [Related]
11. A phase I/II randomized trial of clofarabine or fludarabine added to idarubicin and cytarabine for adults with relapsed or refractory acute myeloid leukemia.
Short NJ; Kantarjian H; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Jabbour E
Leuk Lymphoma; 2018 Apr; 59(4):813-820. PubMed ID: 28718728
[TBL] [Abstract][Full Text] [Related]
12. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group.
Dinndorf PA; Avramis VI; Wiersma S; Krailo MD; Liu-Mares W; Seibel NL; Sato JK; Mosher RB; Kelleher JF; Reaman GH
J Clin Oncol; 1997 Aug; 15(8):2780-5. PubMed ID: 9256119
[TBL] [Abstract][Full Text] [Related]
13. [FLAG regimen as consolidation therapy for patients with acute myeloid leukemia].
Qian SX; Wu HX; Hong M; Lu H; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Dec; 17(6):1577-81. PubMed ID: 20030951
[TBL] [Abstract][Full Text] [Related]
14. FLAG-Ida Regimen as Bridge Therapy to Allotransplantation in Refractory/Relapsed Acute Myeloid Leukemia Patients.
Delia M; Pastore D; Carluccio P; Pasciolla C; Ricco A; Rossi AR; Casieri P; Mestice A; Albano F; Specchia G
Clin Lymphoma Myeloma Leuk; 2017 Nov; 17(11):767-773. PubMed ID: 28864170
[TBL] [Abstract][Full Text] [Related]
15. The clinical outcome of FLAG chemotherapy without idarubicin in patients with relapsed or refractory acute myeloid leukemia.
Lee SR; Yang DH; Ahn JS; Kim YK; Lee JJ; Choi YJ; Shin HJ; Chung JS; Cho YY; Chae YS; Kim JG; Sohn SK; Kim HJ
J Korean Med Sci; 2009 Jun; 24(3):498-503. PubMed ID: 19543516
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine and cytarabine versus high-dose cytarabine in consolidation treatment of t(8; 21) acute myeloid leukemia: A prospective, randomized study.
Li R; Hu X; Wang L; Cheng H; Lv S; Zhang W; Wang J; Yang J; Song X
Am J Hematol; 2017 Jan; 92(1):12-17. PubMed ID: 27673579
[TBL] [Abstract][Full Text] [Related]
17. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
18. IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.
Yavuz S; Paydas S; Disel U; Sahin B
Am J Ther; 2006; 13(5):389-93. PubMed ID: 16988532
[TBL] [Abstract][Full Text] [Related]
19. Continuous infusion of intermediate-dose cytarabine and fludarabine with idarubicin for patients younger than 60 years with resistant acute myeloid leukemia: a prospective, multicenter phase II study.
Kim H; Park JH; Lee JH; Lee JH; Joo YD; Lee WS; Bae SH; Mo Ryoo H; Lee KH;
Am J Hematol; 2009 Mar; 84(3):161-6. PubMed ID: 19195034
[TBL] [Abstract][Full Text] [Related]
20. [IDA-FLAG regimen in treatment of patients with refractory or relapsed acute leukemia].
Qian SX; Li JY; Wu HX; Zhang R; Hong M; Xu W; Qiu HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Apr; 17(2):464-7. PubMed ID: 19379589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
